A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma

Trial Profile

A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs ABT 751 (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top